MIGHTY MEDIC Org.’s Advanced Clinical Major Seminary and Educational Forum on Clinical Lipidology, Metabolic Disorders, Extracorporeal Therapeutic Techniques, and Atherosclerosis Prevention Seminario Clinico Avanzato e formazione continua in Lipidologia Clinica, Disturbi del Metabolismo, Tecniche Terapeutiche Extracorporee e Prevenzione dell’Aterosclerosi Peschiera del Garda, Italy, April 18-19, 2024 LETZTES PROGRAMM


PICTURES OF THE EVENT October 7-8, 2021 – Verona 16th LIPID CLUB AND THERAPEUTIC APHERESIS Seminary and Educational Forum on Clinical Lipidology, Metabolic Disorders, Extracorporeal Therapeutic Techniques and Atherosclerosis Prevention Verona, October 7-8, 2021Camera di Commercio, Industria Artigianato e Agricoltura di Verona Corso Porta Nuova, 96 – 37122 Verona VR …

Continue reading

FCS Announcement

We are collecting anonymised information on patients with familial chylomicronaemia syndrome (FCS)/multifactorial chylomicronaemia syndrome (MCS) as a service evaluation & quality improvement project. The project aims to improve understanding of natural history of FCS and to validate the use of FCS scoring algorithm. The project is approved by Manchester University …

Continue reading

E-ISFA 2020 Announcement

3rd Congress of the European Group – International Society for Apheresis (E-ISFA) Dresden, March 19 to 21, 2020   Congress Topics Recent progress in lipoprotein apheresis Homozygous familial hypercholesterolemia Lipoprotein(a) Competition with drugs Plasma exchange Immunoadsorption – indications, results, future perspectives Experience with extracorporeal therapy in children and during pregnancy Apheresis …

Continue reading

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – a post-hoc analysis of a Phase 3, single-arm, open-label trial.

OBJECTIVE: Lomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis. Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-hoc analysis using data …

Continue reading

The role of microparticles in inflammation and transfusion: a concise review

Abstract Microparticles are small membrane-bound vesicles, found in body fluids including peripheral blood. Microparticles are an intrinsic part of blood labile products delivered to transfused patients and have active roles in inflammation. They are delimited by a lipid bilayer composed mainly of phospholipids, cholesterol, membrane-associated proteins, intracellular components such as metabolic enzymes, proteins-involved …

Continue reading